| Name | Title | Contact Details |
|---|
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
BioGenex Laboratories, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.
Incellico Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CIMA Labs Inc. develops and manufactures orally disintegrating tablet and enhanced-absorption oral drug delivery systems. The Company's lead, orally disintegrating tablet technologies, OraSolv and DuraSolv, allow an active drug ingredient, which is